MAbs 5 (5): 621–623.12 12 Mehr, S.R. and Zimmerman, M.P. (2016). Is a biologic produced 15 years ago a biosimilar of itself today? Am Health Drug Benefits 9 (9): 515–518.
13 13 Webster, C.J. and Woollett, G.R. (2017). A ‘global reference' comparator for biosimilar development. BioDrugs 31 (4): 279–286.
14 14 Diependaele, L., Cockbain, J., and Sterckx, S. (2018). Similar or the same? Why biosimilars are not the solution. J Law Med Ethics 46 (3): 776–790.
15 15 Pani, L., Montilla, S., Pimpinella, G., and Bertini, M.R. (2013). Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity. Expert Opin Biol Ther 13 (10): 1343–1346.
16 16 Blanchard, A., D'Iorio, H., and Ford, R. (2010). What you need to know to succeed: key trends in Canada’s biotech industry. Insight 1 (Spring).
17 17 Mechcatie, E. (2010). FDA asks: when are biosimilars similar enough? Commun Oncol 8 (10): 479–480.
18 18 Murphy, C., Sugrue, K., Mohamad, G. et al. (2015). P505: biosimilar but not the same. Paper presented at 10th Congress of ECCO2015, Barcelona, Spain (January 2015).
19 19 Vijayalakshmi, R., Sabitha, K., and Arvind, K. (2012). How dissimilarly similar are biosimilars? Int Res J Pharm 3 (5): 12–16.
20 20 Ronco, C. (2005). Biosimilars: how similar are they? Int J Artif Organs 28 (6): 552–553.
21 21 Jeffrey, K. and Ferner, R. (2016). How similar are biosimilars? BMJ Online 353: i2721.
22 22 Gupta, P. (2017). Biosimilars: similar but not the same. JK Sci 19 (2): 67–69.
23 23 Dingermann, T. and Zündorf, I. (2007). Biosimilars: similar, but not the same. Dtsch Apoth Ztg 147 (38): 68–74.
24 24 Dingermann, T. and Zündorf, I. (2015). Same, similar or different? How biosimilars can differ from originals. Dtsch Apoth Ztg 155 (7).
25 25 Schellekens, H. (2004). How similar do ‘biosimilars' need to be? Nat Biotechnol 22 (11): 1357–1359.
26 26 Schellekens, H. and Moors, E. (2015). Biosimilars or semi‐similars? Nat Biotechnol 33 (1): 19–20.
27 27 Rudolf, T., Brinkmann, C., and Bleiziffer, A. (2015). Biosimilars‐necessary alternative or overpriced me‐toos? Pharm Ind 77 (2): 160–165.
28 28 Rolf, D., Parker, J., and Morgan, M. (2016). Are biosimilars patentable? Expert Opin Ther Pat 26 (8): 871–875.
29 29 Guillon‐Munos, A., Daguet, A., and Watier, H. (2014). Antibody biosimilars: fears or opportunities? First LabEx MabImprove Workshop. MAbs 6 (4): 805–809.
30 30 Declerck, P., Danesi, R., Petersel, D., and Jacobs, I. (2017). The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs 77 (6): 671–677.
31 31 Courtois, F., Schneider, C.P., Agrawal, N.J., and Trout, B.L. (2015). Rational design of biobetters with enhanced stability. J Pharm Sci 104 (8): 2433–2440.
32 32 Ebbers, H.C., Crow, S.A., Vulto, A.G., and Schellekens, H. (2012). Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 30 (12): 1186–1190.
33 33 Esplugues, J.V., Flamion, B., and Puig, L. (2016). Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars. New Horiz Transl Med 3 (3–4): 161.
34 34 Moots, R., Azevedo, V., Coindreau, J.L. et al. (2017). Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep 19 (6): 37.
35 35 Biologics Prescribers Collaborative (BPC) (2018). Non‐Medical Switching Principles and Guidelines (16 March). www.biologicsprescribers.org/policy‐issues/non‐medical‐switching (accessed 20 June 2020).
36 36 French, T. (2018). Shared decision making in switching to biosimilars. Ann Rheum Dis 77 (Supplement 2): 7.
37 37 Cvancarova S.M., Brandvold, M., and Andenaes, R. (2018). Is patients' satisfaction with being switched to a biosimilar medication associated with their level of health literacy? Results from a Norwegian user survey. Ann Rheum Dis 77 (Supplement 2): 86.
38 38 McKinnon, R.A., Cook, M., Liauw, W. et al. (2018). Biosimilarity and interchangeability: principles and evidence. A systematic review. BioDrugs 32 (1): 27–52.
39 39 GaBi Online (2018). International policies for interchangeability, switching and substitution of biosimilars. http://gabionline.net/Reports/International‐policies‐for‐interchangeability‐switching‐and‐substitution‐of‐biosimilars (accessed 18 February 2020).
40 40 Milmo, S. (2016). Biosimilars: making the switch comes with challenges. More efforts are needed to raise awareness of biosimilars among physicians and patients in Europe and address scepticisms about the quality and safety of biosimilars. BioPharm Int 29 (6): 10–14.
41 41 Uhlig, T. and Goll, G.L. (2017). Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology (Oxford) 56 (Suppl 4): iv49–iv62.
42 42 Gerrard, T.L., Johnston, G., and Gaugh, D.R. (2015). Biosimilars: extrapolation of clinical use to other indications. GaBI J 4 (3): 118–124.
43 43 McCamish, M. and Woollett, G. (2017). Molecular “sameness” is the key guiding principle for extrapolation to multiple indications. Clin Pharmacol Ther 101 (5): 603–605.
44 44 Pouillon, L., Socha, M., Demore, B. et al. (2018). The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol 14 (9): 739–749.
45 45 Povsic, M., Lavelle, P., Enstone, A., and Rousseau, B. (2018). Patient influence on biosimilar uptake: the nocebo effect. Value Health 21 (Supplement 3): S181.
46 46 Buttel, I.C., Chamberlain, P., Chowers, Y. et al. (2011). Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39 (2): 100–109.
47 47 Strand, V., Goncalves, J., Hickling, T.P. et al. (2018). Immunogenicity of biosimilars for rheumatic diseases: an updated review from regulatory documents and confirmatory clinical trials. Ann Rheum Dis 77 (Supplement 2): 1398.
48 48 World Health Organization, CIOMS (2018). Definitions. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/trainingcourses/definitions.pdf (accessed 20 February 2020).
49 49 European Medicines Agency (2014). Guideline on similar biological medicinal products containing biotechnology‐derived proteins as active substance: non‐clinical and clinical issues. https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐similar‐biological‐medicinal‐products‐containing‐biotechnology‐derived‐proteins‐active_en‐2.pdf (accessed 20 February 2020).
50 50 Calvo,
